Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
Identifieur interne : 001114 ( Main/Corpus ); précédent : 001113; suivant : 001115Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
Auteurs : Eyma Ta Temur ; Hilmi AtasevenSource :
- Medical hypotheses [ 1532-2777 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Drug Repositioning (MeSH), Host Microbial Interactions (drug effects), Host Microbial Interactions (physiology), Humans (MeSH), Hydrogen-Ion Concentration (MeSH), Hydroxychloroquine (therapeutic use), Models, Biological (MeSH), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Proton Pump Inhibitors (therapeutic use), SARS-CoV-2 (MeSH), Virus Internalization (drug effects).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine, Proton Pump Inhibitors.
- drug effects : Betacoronavirus, Host Microbial Interactions, Virus Internalization.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus, Host Microbial Interactions.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- COVID-19, Drug Repositioning, Humans, Hydrogen-Ion Concentration, Models, Biological, SARS-CoV-2.
Abstract
Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.
DOI: 10.1016/j.mehy.2020.110018
PubMed: 32679422
PubMed Central: PMC7834647
Links to Exploration step
pubmed:32679422Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?</title><author><name sortKey="Ta Temur, Eyma" sort="Ta Temur, Eyma" uniqKey="Ta Temur " first=" Eyma" last="Ta Temur"> Eyma Ta Temur</name><affiliation><nlm:affiliation>Department of Internal Medicine, Sivas Numune Hospital, Sivas, Turkey. Electronic address: yaman_seyma@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ataseven, Hilmi" sort="Ataseven, Hilmi" uniqKey="Ataseven H" first="Hilmi" last="Ataseven">Hilmi Ataseven</name><affiliation><nlm:affiliation>Department of Internal Medicine, Discipline of Gastroenterology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey. Electronic address: hilmiataseven@yahoo.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32679422</idno><idno type="pmid">32679422</idno><idno type="doi">10.1016/j.mehy.2020.110018</idno><idno type="pmc">PMC7834647</idno><idno type="wicri:Area/Main/Corpus">001114</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001114</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?</title><author><name sortKey="Ta Temur, Eyma" sort="Ta Temur, Eyma" uniqKey="Ta Temur " first=" Eyma" last="Ta Temur"> Eyma Ta Temur</name><affiliation><nlm:affiliation>Department of Internal Medicine, Sivas Numune Hospital, Sivas, Turkey. Electronic address: yaman_seyma@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ataseven, Hilmi" sort="Ataseven, Hilmi" uniqKey="Ataseven H" first="Hilmi" last="Ataseven">Hilmi Ataseven</name><affiliation><nlm:affiliation>Department of Internal Medicine, Discipline of Gastroenterology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey. Electronic address: hilmiataseven@yahoo.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (physiology)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Drug Repositioning (MeSH)</term><term>Host Microbial Interactions (drug effects)</term><term>Host Microbial Interactions (physiology)</term><term>Humans (MeSH)</term><term>Hydrogen-Ion Concentration (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Models, Biological (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Proton Pump Inhibitors (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Proton Pump Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term><term>Host Microbial Interactions</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term><term>Host Microbial Interactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Drug Repositioning</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Models, Biological</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32679422</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?</ArticleTitle><Pagination><MedlinePgn>110018</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)31166-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.110018</ELocationID><Abstract><AbstractText>Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taştemur</LastName><ForeName>Şeyma</ForeName><Initials>Ş</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sivas Numune Hospital, Sivas, Turkey. Electronic address: yaman_seyma@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ataseven</LastName><ForeName>Hilmi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Discipline of Gastroenterology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey. Electronic address: hilmiataseven@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076662" MajorTopicYN="N">Host Microbial Interactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Proton Pump Inhibitors</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32679422</ArticleId><ArticleId IdType="pii">S0306-9877(20)31166-X</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.110018</ArticleId><ArticleId IdType="pmc">PMC7834647</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):106044</Citation><ArticleIdList><ArticleId IdType="pubmed">32522674</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jun;55(6):105969</Citation><ArticleIdList><ArticleId IdType="pubmed">32278811</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2008 May;31(5):1030-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18216050</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 1992 May;33(5):617-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1319381</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Biosci. 2020 Jul 03;7:157</Citation><ArticleIdList><ArticleId IdType="pubmed">32719810</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2017 Jan 26;8:16</Citation><ArticleIdList><ArticleId IdType="pubmed">28184197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2009 Feb;18(2):104-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19151110</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1505-19</Citation><ArticleIdList><ArticleId IdType="pubmed">22998066</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2019 Dec 03;10:2790</Citation><ArticleIdList><ArticleId IdType="pubmed">31849920</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2006 Jul 7;345(3):1014-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16712795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 May;20(5):269-270</Citation><ArticleIdList><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2019 Sep 19;14(9):e0222779</Citation><ArticleIdList><ArticleId IdType="pubmed">31536596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):201-211</Citation><ArticleIdList><ArticleId IdType="pubmed">32302411</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 1989;36:107-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2500008</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1999 May;43(5):1304-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10223960</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Surg Int. 2005 Oct;21(10):800-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16205929</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015;70(6):1608-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25693996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus Sci Med. 2019 Jun 16;6(1):e000335</Citation><ArticleIdList><ArticleId IdType="pubmed">31275579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 2020 Sep;96(1139):550-555</Citation><ArticleIdList><ArticleId IdType="pubmed">32295814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci China C Life Sci. 2009 May;52(5):464-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19471869</ArticleId></ArticleIdList></Reference><Reference><Citation>Trop Med Int Health. 2020 Mar;25(3):278-280</Citation><ArticleIdList><ArticleId IdType="pubmed">32052514</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2018 May 17;9:499</Citation><ArticleIdList><ArticleId IdType="pubmed">29867501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Jun;64(6):3042-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2159562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1991 Apr;65(4):1916-28</Citation><ArticleIdList><ArticleId IdType="pubmed">1848311</ArticleId></ArticleIdList></Reference><Reference><Citation>Virulence. 2014 Aug 15;5(6):650-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25089913</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2015 May;67(8):2176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25989906</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2002 Nov 15;281(1):86-100</Citation><ArticleIdList><ArticleId IdType="pubmed">12441132</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Chemother. 2009 Dec;15(6):374-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20012727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vector Borne Dis. 2006 Dec;43(4):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17175700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001114 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001114 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32679422
|texte= Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32679422" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |